Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Aprea Therapeutics Q3 2026 Results: Net Loss of $4.81M, Loss Widens

Aprea Therapeutics reported a net loss of $11.7 million for the nine months ended September 30, 2026, compared to a $10.1 million loss in the prior year period, driven primarily by increased research and development expenses. The company significantly strengthened its liquidity, ending the period with $37.8 million in cash and cash equivalents following equity financing activities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.8-3.0
EPS (diluted, $ a share)$-0.09$-0.47

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: APRE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Aprea Therapeutics, Inc.: key numbers

Share price
$0.4063Close, Nov 16
Market cap
$5.77M
Shares outstanding
14.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Aprea Therapeutics, Inc.

All →
8:40 AM ET 8-K
Financial Results

Aprea Therapeutics Financial Results

Aprea Therapeutics reported third quarter 2026 financial results and provided a clinical update on its oral WEE1 inhibitor, APR-1051. The company expanded its Phase 1 clinical trial network to nine sites and expects to select a dose for the optimization phase of the study in the first half of 2027.

“We continue to make meaningful progress in advancing APR-1051 towards our goal of developing a differentiated, potentially best-in-class WEE1 inhibitor for patients with biomarker defined cancers.”

Oren Gilad, Ph.D., President and Chief Executive Officer

“With $37.8 million in cash and cash equivalents as of September 30, 2026, and an expected cash runway into the first quarter of 2028, we believe we are well positioned to execute our clinical development strategy, achieve meaningful milestones, and create long-term value for patients and shareholders.”

Oren Gilad, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.